NICECACTUS/GLORY4GAMERS
26.2.2020 14:02:11 CET | Business Wire | Press release
Following the announcement of an initial funding round of €5 million at the end of 2019, Nicecactus has taken yet another step forward in its global development by acquiring Glory4Gamers. The strategic alliance of these two esports experts provides 1 million users with an all-in-one solution, combining knowledge in training and skill development as well as in organizing both online and offline tournaments. Players, partners and B2B customers alike can now benefit from the comprehensive range of services of these two stakeholders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200226005081/en/
Since the end of January 2020, Nicecactus and Glory4Gamers have combined their expertise and solutions with the ambition to further expand internationally. The G4G teams have joined the Nicecactus family to form a 70-person team. They are reinforcing the already successful model of tournaments and competitions with prize money for players of all levels. In addition, the offline B2B event package, which enables brands (sponsors and publishers) to run promotional campaigns among qualified audiences, will be developed to become one of the pillars of the Nicecactus offer.
An all-in-one platform for aspiring champions
Amateur or semi-professional players, members of the Glory4Gamers and nicecactus.gg platforms, will now benefit from a complete solution empowering them with the professional training method they need to reach their full potential and realize their dream of becoming champions. It ranges from tailor-made training sessions (tutorials and drills), to performance assessment and analysis tools, as well as daily competitions with prizes and even networking with professional players in the sector (sponsors, teams) for the most talented of them.
All players are also eligible for the Nicecactus Grassroots Esports Fund, a $1 million grant program, through which they can cover travel and accommodation expenses to participate in bootcamps at professional training locations or tournaments they have qualified for.
“The decision to acquire Glory4Gamers fits perfectly with our strategy to develop and strengthen our unique offer, which encompasses virtually all aspects of esports, from amateurs to semi-professional players, as well as companies wishing to address this highly qualified target audience,” explains Mike Hessabi, Founder & President of Nicecactus.
"The esports market is growing at breakneck speed, and we want more than ever to be at the heart of this ecosystem. Nicecactus approaches esports with an innovative vision and great ambitions. The combination of Glory4Gamers and Nicecactus felt obvious to us, as we have a very aligned vision and complementary skills," adds Cyril Chomette, CEO and Founder of Glory4Gamers.
About Nicecactus:
First ever all-encompassing esports platform, Nicecactus took root in the sun-bathed French Riviera. Its goal is to foster aspiring esports players who wish to unleash their gaming potential and master their game. Nicecactus provides them with a professional training method as well as all the tools they need to fulfill their dream of becoming champions. Players from all over the world are encouraged to give the best out of themselves, through a continued training program, a fined-tuned stats tracking system and the opportunity to compete in tournaments and make some cash out of their passion in a challenging and fun way. Its first-of-its-kind Nicecactus Grassroots Esports Fund rewards the best players for their talent and dedication by connecting them to the professional world. www.nicecactus.gg
About Glory4Gamers:
Founded in 2012, Glory4Gamers is a pioneer in amateur esports. Now the leading organizer of esports tournaments in France and 3rd in Europe, the platform holds more than 2,000 tournaments per month. Through its unique real-time refereeing component, Glory4Gamers promises its users a unique esports experience, in a fun and fair play environment, and with a human support close at hand.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005081/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
